{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:19:55Z","timestamp":1791623995548,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jfma.2023.07.017","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T01:30:06Z","timestamp":1691544606000},"page":"198-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of comorbidities, neutrophil-to-lymphocyte ratio, and drug toxicities on quality of life in lung cancer patients receiving EGFR-TKI therapy"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3336-6661","authenticated-orcid":false,"given":"Jung-Yueh","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-2293","authenticated-orcid":false,"given":"Sheng-Kai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Yi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-3279","authenticated-orcid":false,"given":"Chia-Yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jo","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2023.07.017_bib1","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin 2020"},{"key":"10.1016\/j.jfma.2023.07.017_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.jfma.2023.07.017_bib3","series-title":"NCCN clinical practice guidelines in Oncology","year":"2020"},{"key":"10.1016\/j.jfma.2023.07.017_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.07.017_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.jfma.2023.07.017_bib8","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.07.017_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib10","article-title":"A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy","volume":"27","author":"Chan","year":"2019","journal-title":"J Nurs Res"},{"key":"10.1016\/j.jfma.2023.07.017_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020510","article-title":"Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: an observational study","volume":"99","author":"Tseng","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2023.07.017_bib12","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.7150\/jca.30507","article-title":"Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - a multicenter prospective SMILE study","volume":"10","author":"Wei","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib13","doi-asserted-by":"crossref","first-page":"1601721","DOI":"10.1183\/13993003.01721-2016","article-title":"Comorbidities in the management of patients with lung cancer","volume":"49","author":"Leduc","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jfma.2023.07.017_bib14","doi-asserted-by":"crossref","first-page":"1252897","DOI":"10.1155\/2018\/1252897","article-title":"Effect of comorbidity on lung cancer diagnosis timing and mortality: a nationwide population-based cohort study in Taiwan","volume":"2018","author":"Dima","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jfma.2023.07.017_bib15","doi-asserted-by":"crossref","first-page":"19872","DOI":"10.1038\/s41598-019-56431-w","article-title":"Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients","volume":"9","author":"Kitazawa","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2023.07.017_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2010.31.3049","article-title":"Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review","volume":"29","author":"Lee","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11136-005-8661-z","article-title":"Relationship between multimorbidity and health-related quality of life of patients in primary care","volume":"15","author":"Fortin","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jfma.2023.07.017_bib18","doi-asserted-by":"crossref","first-page":"e002571","DOI":"10.1136\/bmjopen-2013-002571","article-title":"The effect of multiple chronic conditions on self-rated health, disability and quality of life among the older populations of Northern Ireland and the Republic of Ireland: a comparison of two nationally representative cross-sectional surveys","volume":"3","author":"McDaid","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfma.2023.07.017_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/pcan.2010.33","article-title":"From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer","volume":"13","author":"Daskivich","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jfma.2023.07.017_bib20","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.ejca.2010.04.009","article-title":"Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy","volume":"46","author":"Gr\u00f8nberg","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib21","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/cncr.22615","article-title":"Assessment of prognosis with the total illness burden index for prostate cancer","volume":"109","author":"Litwin","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s12094-012-0872-5","article-title":"Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer","volume":"14","author":"Cedr\u00e9s","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061426","article-title":"Neutrophil-to-Lymphocyte ratio is a predictive biomarker in patients with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitor (TKI) therapy","volume":"13","author":"Yun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jfma.2023.07.017_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3892\/mco.2017.1342","article-title":"Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients","volume":"7","author":"Yu","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst: J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2023.07.017_bib26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","article-title":"A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson\u2019s index","volume":"93","author":"Colinet","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jfma.2023.07.017_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jdv.15121","article-title":"Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life","volume":"33","author":"Ho","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2023.07.017_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2340\/00015555-1265","article-title":"Visual analogue scale: evaluation of the instrument for the assessment of pruritus","volume":"92","author":"Reich","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jfma.2023.07.017_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst: J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2023.07.017_bib31","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1634\/theoncologist.2019-0348","article-title":"The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the \u201cReal-World\u201d: results from the population-based PROFILES registry","volume":"25","author":"Husson","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib32","first-page":"149","volume":"123","author":"Pompili","year":"2018","journal-title":"EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC), Lung Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jfma.2023.07.017_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in Oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.jfma.2023.07.017_bib35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.ejca.2015.04.004","article-title":"Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: results from the population-based PROFILES registry","volume":"51","author":"Verhaar","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib36","article-title":"Quality of life in long term survivors of colorectal cancer","volume":"97","author":"Ramsey","year":"2002","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"key":"10.1016\/j.jfma.2023.07.017_bib37","doi-asserted-by":"crossref","DOI":"10.3747\/co.21.2241","article-title":"Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors","volume":"21","author":"Hirsh","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib38","first-page":"154","article-title":"Cancer anorexia - cachexia syndrome","volume":"44","author":"Muliawati","year":"2012","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.jfma.2023.07.017_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/NJH.0b013e31825f3470","article-title":"Management of anorexia-cachexia in late stage lung cancer patients, the official journal of the Hospice and Palliative Nurses Association","volume":"14","author":"Del Ferraro","year":"2012","journal-title":"J Hospice Palliat Nurs"},{"key":"10.1016\/j.jfma.2023.07.017_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.critrevonc.2015.12.008","article-title":"Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: a systematic review","volume":"99","author":"Tarricone","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jfma.2023.07.017_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jcsm.12059","article-title":"Pathophysiology of anorexia in the cancer cachexia syndrome","volume":"6","author":"Ezeoke","year":"2015","journal-title":"Journal of cachexia, sarcopenia and muscle"},{"key":"10.1016\/j.jfma.2023.07.017_bib43","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1038\/s41598-020-64282-z","article-title":"An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer","volume":"10","author":"Barker","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2023.07.017_bib44","first-page":"697","article-title":"Health-related quality of life and inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Kao","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis","volume":"69","author":"Ensslin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2023.07.017_bib46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5021\/ad.2012.24.4.406","article-title":"Effect of the pruritus on the quality of life: a preliminary study","volume":"24","author":"Erturk","year":"2012","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jfma.2023.07.017_bib47","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: the skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jfma.2023.07.017_bib48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaad.2013.02.025","article-title":"Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer","volume":"69","author":"Kiyohara","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2023.07.017_bib49","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","article-title":"A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson\u2019s index","volume":"93","author":"Colinet","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2023.07.017_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/jpm5030229","article-title":"Comorbidities and quality of life among breast cancer survivors: a prospective study","volume":"5","author":"Fu","year":"2015","journal-title":"J Personalized Med"},{"key":"10.1016\/j.jfma.2023.07.017_bib51","doi-asserted-by":"crossref","first-page":"e020512","DOI":"10.1136\/bmjopen-2017-020512","article-title":"Health-related quality of life in Asian patients with breast cancer: a systematic review","volume":"8","author":"Ho","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfma.2023.07.017_bib52","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jtho.2018.11.019","article-title":"Quality of life in NSCLC survivors - 2014; A multicenter cross-sectional study","volume":"14","author":"Hechtner","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jfma.2023.07.017_bib53","doi-asserted-by":"crossref","first-page":"10693","DOI":"10.1038\/s41598-020-67604-3","article-title":"The major effects of health-related quality of life on 5-year survival prediction among lung cancer survivors: applications of machine learning","volume":"10","author":"Sim","year":"2020","journal-title":"Sci Rep"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623002917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623002917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:52:30Z","timestamp":1760539950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664623002917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0929664623002917"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2023.07.017","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of comorbidities, neutrophil-to-lymphocyte ratio, and drug toxicities on quality of life in lung cancer patients receiving EGFR-TKI therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2023.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}